Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 5 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Anti-TNF-α also helps with anaemia in IBD patients

09 Jan 2020
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Using anti-tumour necrosis factor-α (TNF-α) agents to treat inflammatory bowel diseases (IBD) also improves haemoglobin levels and may help resolve anaemia, a recent study has shown.

Researchers analysed the data of 362 IBD patients (mean age at recruitment, 35.1 years; 61 percent male) who were treated with anti-TNF-α drugs. Study outcomes were the treatment effects on disease activity, anaemia prevalence and blood markers after 6 and 12 months of medication.

Prior to initiating anti-TNF-α treatment, the mean haemoglobin concentration in the overall cohort was 13.2±1.9 g/dL; this was slightly higher in those with Crohn’s disease (CD) than in their ulcerative colitis (UC) counterparts. After 6 months of treatment, haemoglobin levels jumped to 14±1.7 in the overall cohort, with equivalent increases in the CD and UC subgroups. All changes were statistically significant when compared to baseline (p<0.001).

This increase continued until after 12 months of treatment, though changes relative to month 6 failed to achieve statistical significance.

Anti-TNF-α likewise had significant benefits on anaemia prevalence. At baseline, 29.3 percent (n=106) of all patients had anaemia (35.2 percent in UC patients and 27.3 percent in CD patients; p=0.154). This dropped to 14.4 percent (n=49) after 6 months of treatment (16.3 percent and 13.8 percent in the respective subgroups). By month 12, only 25 patients (7.8 percent) were anaemic.

The medication also resulted in drops in disease activity, as measured by serum levels of C-reactive protein (2.01±3.9 mg/dL at baseline to 0.81±2.2 mg/dL after 6 months, and to 0.44±0.7 mg/dL after 12 months; p<0.001 for both comparisons).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 5 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).